(Q54245802)

English

Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

U Jehn

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

V Heinemann

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

publication date

1 March 1993

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

66

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

131-134

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I-II clinical and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

High dose cytosine arabinoside in the management of refractory acute leukaemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rationales for a pharmacologically optimized treatment of acute nonlymphocytic leukemia with cytosine arabinoside.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/8471658

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/BF01697622

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

release_6wjbs53fy5crlpgkbh7b6k3eee

1 reference

https://api.fatcat.wiki/v0/release/6wjbs53fy5crlpgkbh7b6k3eee

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/8471658

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54245802&oldid=1840477640"